Aatru Medical, a Cleveland-based medtech company, completed a Series C financing round for an undisclosed amount with private investors.
The company said it would use the funds to support development of its Negative Pressure Surgical Incision Management System through FDA clearance, as well as for other short-term needs.
"Our investors have continued to show strong confidence in our efforts since our inception almost 5 years ago," Aatru CEO Timothy Wojciechowski said in a statement. "Because of their support, we have been able to systematically move our NPSIMS product from concept to reality, creating an innovative and disruptive alternative to traditional [negative-pressure wound therapy] devices for surgical incisions. We have partnered with best-in-class manufacturers to ensure we meet global demands and have built a substantial portfolio of over 40 patents filed globally to protect our innovation."
